BCG vaccine for clinically isolated syndrome and MS
Infections and protective immunity
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published December 4, 2013.
Article Versions
- Previous version (December 4, 2013 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Dennis Bourdette, MD, FAAN, FANA and
- Robert T. Naismith, MD
- Dennis Bourdette, MD, FAAN, FANA and
I serve on a scientific advisory board for the non-profit entity NYSTEM
NONE
I have received honoraria for speaking from Biogen Idec, Teva Neurosciences and Genzyme.
Journal of Medicinal Medicine, Associate Editor, 2009-present ; Current Neurology and Neuroscience Reports, Section Editor, 2008-present; Autoimmune Diseases, Associate Editor, 2009-present; Neurology, Member Editorial Board, 2013-present present. I receive no compensation for any of these activities.
I have a use patent pending for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin.
NONE
NONE
I have served as a consultant to Teva Neurosciences and Biogen Idec in the past 12 months.
NONE
I have received support for patient and physician education programs from Teva Neuroscience, Biogen Idec, EMD Serono, Accorda and Novartis.
NONE
NONE
1. Department of Veterans Affairs/BLR&D, Merit Review, PI, 10/1/09-9/30/13 2. Department of Veterans Affairs/Rehabilitation R&D, Merit Review, 1/1/12-12/31/15
NONE
NONE
NONE
NONE
Use patent pending for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin, royalty payment from DebioPharma in 2012 and 2013.
NONE
NONE
NONE
- Robert T. Naismith, MD
NONE
NONE
1) Acorda Therapeutics, speaker honoraria and travel (commercial) 2) Bayer Healthcare, speaker honoraria and travel (commercial) 3) Biogen IDEC, speaker honoraria and travel (commercial) 4) Genzyme Corporation, speaker honoraria and travel (commercial) 5) National MS Society, speaker honoraria and travel (not-for profit) 6) Consortium MS Centers, speaker honoraria and travel (not-for-profit) 7) EMD Serono, consulting honoraria and travel (commercial) 8) Questcor Therapeutics, consulting honoraria and travel (commercial)
Journal Watch 2010-present, Associate Editor
NONE
NONE
NONE
NONE
1) Acorda Therapeutics (commercial) 2) Bayer Healthcare (commercial) 3) Biogen Idec (commercial) 4) Genzyme Corporation (commercial)
NONE
NONE
Acorda Therapeutics - Washington University site PI for national Fampridine SR clinical trial, 2004-2010. Dalfampridine for vision after optic neuritis in MS, 2011-present.
NIH funding included K23NS052430-01A1
NONE
National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (D.B.), Oregon Health & Science University and Multiple Sclerosis Centers of Excellence-West, Veterans Affairs Medical Center, Portland; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO.
- Correspondence to Dr. Bourdette: bourdett{at}ohsu.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.